Skip to main content
Log in

Therapie mit Sunitinib

Ist die zytoreduktive Nephrektomie beim mRCC noch Standard?

  • journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Méjean A et al. N Engl J Med. 2018;379(5):417–27

    Article  Google Scholar 

  2. Mickisch GH et al. Lancet. 2001;358(9286):966–70

    Article  CAS  Google Scholar 

  3. Choueiri TK et al. J Clin Oncol. 2017;35(6):591–7

    Article  CAS  Google Scholar 

  4. Motzer RJ et al. N Engl J Med. 2018;378(14):1277–90

    Article  CAS  Google Scholar 

  5. Rini BI et al. Lancet Oncol. 2016;17(9):1317–24

    Article  Google Scholar 

  6. Bhindi B et al. Eur Urol. 2019;75(1):111–28

    Article  Google Scholar 

  7. Culp SH et al. Cancer. 2010;116(14):3378–88

    Article  Google Scholar 

  8. Bex A et al. JAMA Oncol. 2018; https://doi.org/10.1001/jamaoncol.2018.5543

    Google Scholar 

  9. Bex A et al. Eur Urol. 2018;74(6):805–9

    Article  Google Scholar 

Literatur

  • Méjean A et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018;379(5):417–27

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christoph Oing.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oing, C., Bokemeyer, C. Ist die zytoreduktive Nephrektomie beim mRCC noch Standard?. Info Onkol. 22, 16–17 (2019). https://doi.org/10.1007/s15004-019-6421-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6421-4

Navigation